scholarly journals Screening for Anti-Food Immunoglobulin G of Human Plasma and an Intravenous Immunoglobulin Preparation (Gammagard Liquid)

2021 ◽  
Vol 147 (2) ◽  
pp. AB103
Author(s):  
Alfred Weber ◽  
Andrea Engelmaier
BioDrugs ◽  
2017 ◽  
Vol 31 (3) ◽  
pp. 251-261 ◽  
Author(s):  
Caroline Goussen ◽  
Steve Simoneau ◽  
Soline Bérend ◽  
Christine Jehan-Kimmel ◽  
Anne Bellon ◽  
...  

2014 ◽  
Vol 163 (6) ◽  
pp. 557-564 ◽  
Author(s):  
Angela S.W. Tjon ◽  
Haziz Jaadar ◽  
Rogier van Gent ◽  
Peter J.S. van Kooten ◽  
Najib Achatbi ◽  
...  

2014 ◽  
Vol 41 (3) ◽  
pp. 205-212 ◽  
Author(s):  
Inga A. Laursen ◽  
Lene Blou ◽  
John S. Sullivan ◽  
Peter Bang ◽  
Flemming Balstrup ◽  
...  

2010 ◽  
Vol 46 (4) ◽  
pp. 777-783
Author(s):  
Antônio Edson de Souza Lucena ◽  
Divaldo de Almeida Sampaio ◽  
Ednaldo Rosas da Silva ◽  
Virgínia Florêncio de Paiva ◽  
Ana Cláudia Santiago ◽  
...  

Highly purified intravenous immunoglobulin G concentrate (IV IgG) was produced with the use of polyethylene glycol associated to a single-stage precipitation by ethanol, instead of the classic Cohn-Oncley process, which employs cold alcohol as the precipitating agent, in a three-stage process. Precipitation of crude fraction containing more than 95% of immunoglobulin G was performed by liquid chromatography with a cation exchanger, CM-Sepharose, as a stationary phase. During the process, the product was subjected to two-stage viral inactivation. The first stage was performed by the action of sodium caprylate, 30 mM at pH 5.1+/- 0.1, and the second stage was performed by the action of a solvent-detergent mixture. The finished product was formulated at 5% with 10% sucralose as the stabilizing agent. The process yields 3.3g of IgG/liter of plasma. The finished product analysis showed an anti-complementary activity lower than 1CH50. Polymer and aggregate percent levels were lower than 3% in the five batches studied. The analysis of neutralizing capacity showed the presence of antibacterial and antiviral antibodies in at least three times higher concentrations than the levels found in source plasma. The finished product fulfilled all purity requirements stated in the 4th edition of the European pharmacopeia.


1990 ◽  
Vol 89 (5) ◽  
pp. 554-560 ◽  
Author(s):  
Phillip K. Peterson ◽  
Judy Shepard ◽  
Mark Macres ◽  
Carlos Schenck ◽  
John Crosson ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document